Deutsche Bank Reports Positive Surgery Data From Omeros

Deutsche Bank has issued a report on the positive results from the Ph 2b trial of OMS302 from Omeros

. According to the report, "We are encouraged by the positive cataract surgery study results and the success of Omeros' PharmacoSurgery programs to date. Importantly, we continue to expect pivotal results from the company's lead product candidate OMS103HP (ACL surgery) in the coming weeks. If the pivotal data is positive, Omeros should be on track to file an NDA for OMS103HP in 2Q11. We continue to project a 2H12 OMS103HP launch and believe that this candidate could ultimately achieve peak sales of $500M+ if approved and successfully commercialized." OMER has a Buy Rating and a $13.00 Price Target. OMER closed yesterday at $6.05 a share.